BRPI0914121A2 - derivado de triazol ou sal do mesmo - Google Patents
derivado de triazol ou sal do mesmoInfo
- Publication number
- BRPI0914121A2 BRPI0914121A2 BRPI0914121A BRPI0914121A BRPI0914121A2 BR PI0914121 A2 BRPI0914121 A2 BR PI0914121A2 BR PI0914121 A BRPI0914121 A BR PI0914121A BR PI0914121 A BRPI0914121 A BR PI0914121A BR PI0914121 A2 BRPI0914121 A2 BR PI0914121A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- triazole derivative
- triazole
- derivative
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008-174181 | 2008-07-03 | ||
| JP2008174181 | 2008-07-03 | ||
| PCT/JP2009/062081 WO2010001946A1 (ja) | 2008-07-03 | 2009-07-02 | トリアゾール誘導体またはその塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0914121A2 true BRPI0914121A2 (pt) | 2015-10-20 |
| BRPI0914121B1 BRPI0914121B1 (pt) | 2019-08-06 |
| BRPI0914121B8 BRPI0914121B8 (pt) | 2021-05-25 |
Family
ID=41466037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0914121A BRPI0914121B8 (pt) | 2008-07-03 | 2009-07-02 | derivado de triazol ou sal do mesmo |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8377923B2 (pt) |
| EP (1) | EP2298747B1 (pt) |
| JP (1) | JP5494482B2 (pt) |
| KR (1) | KR101589775B1 (pt) |
| CN (1) | CN102076671B (pt) |
| AU (1) | AU2009266756B2 (pt) |
| BR (1) | BRPI0914121B8 (pt) |
| CA (1) | CA2729408C (pt) |
| CY (1) | CY1118501T1 (pt) |
| DK (1) | DK2298747T3 (pt) |
| ES (1) | ES2620657T3 (pt) |
| HR (1) | HRP20170029T1 (pt) |
| HU (1) | HUE031419T2 (pt) |
| IL (1) | IL210316A (pt) |
| LT (1) | LT2298747T (pt) |
| MX (1) | MX2011000179A (pt) |
| PL (1) | PL2298747T3 (pt) |
| PT (1) | PT2298747T (pt) |
| RS (1) | RS55664B1 (pt) |
| RU (1) | RU2501791C2 (pt) |
| SI (1) | SI2298747T1 (pt) |
| SM (1) | SMT201700154T1 (pt) |
| TW (1) | TWI465439B (pt) |
| WO (1) | WO2010001946A1 (pt) |
| ZA (1) | ZA201100032B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009049662A1 (de) * | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| UA112418C2 (uk) | 2010-09-07 | 2016-09-12 | Астеллас Фарма Інк. | Терапевтичний болезаспокійливий засіб |
| US9006273B2 (en) | 2011-07-29 | 2015-04-14 | Daiichi Sankyo Company, Limited | N-hetero-ring-substituted amide derivative |
| PE20181519A1 (es) * | 2011-12-28 | 2018-09-21 | Global Blood Therapeutics Inc | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido |
| BR112015002526B1 (pt) * | 2012-08-07 | 2022-09-06 | Basilea Pharmaceutica Ag | Derivado do (2r,3r)-éster do ácido 3-hidróxi-2-metil-4 [1,2,4]triazol-1-il-3-fenil-butírico, mistura de diastereoisômeros do referido éster e seu processo de fabricação |
| CN105037285A (zh) * | 2015-07-13 | 2015-11-11 | 佛山市赛维斯医药科技有限公司 | 三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途 |
| BR112020005174A2 (pt) * | 2017-09-14 | 2020-11-10 | Daiichi Sankyo Company,Limited | composto que possui estrutura cíclica |
| US12220412B2 (en) | 2018-11-20 | 2025-02-11 | Sparrow Pharmaceuticals, Inc. | Methods for administering corticosteroids |
| EP4525983A4 (en) | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS |
| AU2024206778A1 (en) * | 2023-01-06 | 2025-07-24 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating hsd-1-mediated disorders |
| CN116621735B (zh) * | 2023-05-19 | 2025-12-19 | 中国医学科学院放射医学研究所 | 偕胺肟基团配体、及其在制备金属-有机框架材料中的应用 |
| WO2024109642A1 (zh) * | 2023-07-28 | 2024-05-30 | 常州大学 | 一种苯并氮杂环类化合物作为β2-肾上腺素受体别构调节剂的应用 |
| WO2025252661A1 (en) * | 2024-06-03 | 2025-12-11 | Immunic Ag | Reducing body weight and/or induction of satiety by triazolo compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3907821A (en) | 1974-11-20 | 1975-09-23 | Upjohn Co | 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone |
| US4577020A (en) | 1983-01-25 | 1986-03-18 | The Upjohn Company | Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents |
| IL84093A (en) | 1986-10-09 | 1992-09-06 | Ciba Geigy Ag | Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them |
| DE4425144A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
| WO2003059267A2 (en) | 2001-12-21 | 2003-07-24 | Rhode Island Hospital | SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| EP1474139B1 (en) | 2002-02-01 | 2007-11-21 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| AR040241A1 (es) * | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2004089896A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| ES2338656T3 (es) | 2003-04-11 | 2010-05-11 | High Point Pharmaceuticals, Llc | Uso farmaceutico de 1,2,4-triazoles fusionados. |
| WO2004089367A1 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| DE602004028473D1 (de) | 2003-05-29 | 2010-09-16 | Merck Sharp & Dohme | Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1 |
| WO2005044192A2 (en) | 2003-10-28 | 2005-05-19 | Amgen Inc. | Triazole compounds and uses related thereto |
| JP2005170939A (ja) * | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| EP1725231A1 (en) | 2003-12-22 | 2006-11-29 | Eli Lilly And Company | Triazole, oxadiazole and thiadiazole derivatives as ppar modulators for the treatment of diabetes |
| WO2005097759A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| RU2383536C2 (ru) | 2004-08-04 | 2010-03-10 | Тайсо Фармасьютикал Ко., Лтд. | Производное триазола |
| KR101214665B1 (ko) * | 2004-09-16 | 2012-12-21 | 아스텔라스세이야쿠 가부시키가이샤 | 트리아졸 유도체 또는 그의 염 |
| WO2006068199A1 (ja) | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体 |
| JPWO2006080533A1 (ja) | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| WO2007007688A1 (ja) | 2005-07-08 | 2007-01-18 | Mochida Pharmaceutical Co., Ltd. | ３,５－ジアミノ－１,２,４－トリアゾール誘導体 |
| WO2007061661A2 (en) * | 2005-11-22 | 2007-05-31 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| CA2645712A1 (en) | 2006-03-16 | 2007-09-20 | Astellas Pharma Inc. | Triazole derivative or salt thereof |
-
2009
- 2009-07-02 EP EP09773524.5A patent/EP2298747B1/en active Active
- 2009-07-02 US US13/002,373 patent/US8377923B2/en active Active
- 2009-07-02 DK DK09773524.5T patent/DK2298747T3/en active
- 2009-07-02 JP JP2010519097A patent/JP5494482B2/ja active Active
- 2009-07-02 WO PCT/JP2009/062081 patent/WO2010001946A1/ja not_active Ceased
- 2009-07-02 HU HUE09773524A patent/HUE031419T2/en unknown
- 2009-07-02 RS RS20170105A patent/RS55664B1/sr unknown
- 2009-07-02 AU AU2009266756A patent/AU2009266756B2/en active Active
- 2009-07-02 PL PL09773524T patent/PL2298747T3/pl unknown
- 2009-07-02 MX MX2011000179A patent/MX2011000179A/es active IP Right Grant
- 2009-07-02 PT PT97735245T patent/PT2298747T/pt unknown
- 2009-07-02 TW TW098122420A patent/TWI465439B/zh active
- 2009-07-02 CA CA2729408A patent/CA2729408C/en active Active
- 2009-07-02 HR HRP20170029TT patent/HRP20170029T1/hr unknown
- 2009-07-02 BR BRPI0914121A patent/BRPI0914121B8/pt active IP Right Grant
- 2009-07-02 SM SM20170154T patent/SMT201700154T1/it unknown
- 2009-07-02 SI SI200931593T patent/SI2298747T1/sl unknown
- 2009-07-02 RU RU2011103789/04A patent/RU2501791C2/ru active
- 2009-07-02 CN CN2009801259400A patent/CN102076671B/zh active Active
- 2009-07-02 KR KR1020117000033A patent/KR101589775B1/ko active Active
- 2009-07-02 LT LTEP09773524.5T patent/LT2298747T/lt unknown
- 2009-07-02 ES ES09773524.5T patent/ES2620657T3/es active Active
-
2010
- 2010-12-28 IL IL210316A patent/IL210316A/en active IP Right Grant
-
2011
- 2011-01-03 ZA ZA2011/00032A patent/ZA201100032B/en unknown
-
2017
- 2017-01-25 CY CY20171100111T patent/CY1118501T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0914121A2 (pt) | derivado de triazol ou sal do mesmo | |
| BRPI0818201A2 (pt) | Composto de azolcarboxamida ou sal do mesmo | |
| EP1988083A4 (en) | triazole | |
| EP2194045A4 (en) | Substituted pyrazole derivative | |
| IL212186A0 (en) | Fungicidal heterocyclic compounds | |
| BRPI0816461A2 (pt) | Derivados fungicidas de 2-alquiltio-2-quinolonolóxi-acetamida | |
| GB0813603D0 (en) | Ventricular assist system | |
| BRPI0912855A2 (pt) | derivados de indazóis substituídos por fenila ou piridinila | |
| ZA201005097B (en) | Herbicidal compounds | |
| GB0800856D0 (en) | Herbicidal compounds | |
| GB0805318D0 (en) | Herbicidal compounds | |
| BRPI0820743A2 (pt) | Carretel de função | |
| BRPI0821773A2 (pt) | Monossebacato derivado de pirazol | |
| ATE555785T1 (de) | Triazolderivate als smo-antagonisten | |
| BRPI0812359A2 (pt) | Derivado de tetra-hidroisoquinolin-1-ona ou sal do mesmo | |
| BRPI0821357A2 (pt) | derivados de oxadiazois de triazol | |
| GB2454967B (en) | Animal trap | |
| BRPI0811103A2 (pt) | Compostos triazol para tratamento de formação de biopelícula | |
| GB2447924B (en) | An animal access system | |
| BR112013014362A2 (pt) | compostos de triazol iii | |
| EP2172458A4 (en) | pyrazolone | |
| BRPI0812223A2 (pt) | Realce do sal | |
| BRPI0918536A2 (pt) | sal de derivado de morfolina | |
| BRPI0820811A2 (pt) | formulação de sal estável de elsamitrucina | |
| ITPE20060008U1 (it) | Disuasivo per animali |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |